Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 35, 2021 - Issue 22
227
Views
2
CrossRef citations to date
0
Altmetric
Research Articles

Anti-leukemic activity of semisynthetic derivatives of lupeol

, , , &
Pages 4494-4501 | Received 04 Sep 2019, Accepted 15 Feb 2020, Published online: 17 Mar 2020

References

  • American Cancer Society. 2016. [accessed 2018 April 02]. http://www.cancer.org/cancer/leukemia-acutelymphocyticallinadults/detailedguide/leukemia-acute-lymphocytic-treating-typical-treatment.
  • Aratanechemuge Y, Hibasami H, Sanpin K, Katsuzaki H, Imai K, Komiya T. 2004. Induction of apoptosis by lupeol isolated from mokumen (Gossampinus malabarica L. Merr) in human promyelotic leukemia HL-60 cells. Oncol Rep. 11(2):289–291.
  • Betancor C, Freire R, Gonzalez AG, Salazar JA, Pascard C, Prange T. 1980. Three triterpenes and other terpenoids from Catha cassinoides. Phytochemistry. 19(9):1989–1993.
  • Cragg GM, Newman DJ. 2013. Natural products: a continuing source of novel drug leads. Biochim. Biophys. Acta. 830:3670–3695.
  • De Corte BL. 2016. Underexplored opportunities for natural products in drug discovery. J Med Chem. 59:9295–9304.
  • Ganesan A. 2008. The impact of natural products upon modern drug discovery. Curr Opin Chem Biol. 12 (3):306–317.
  • Gutiérrez-Nicolás F, Gordillo-Román B, Oberti JC, Estévez-Braun A, Ravelo AG, Joseph-Nathan P. 2012. Synthesis and anti-HIV activity of lupane and olean-18-ene derivatives. Absolute configuration of 19,20-epoxylupanes by VCD. J Nat Prod. 75(4):669–676.
  • Hamid AA, Aiyelaagbe OO, Kaneez F, Luqman S, Negi AS. 2017. Isolation, characterization and antiproliferative evaluation of constituents from stem extracts of Alafia barteri Oliv. Hook. F. Med Chem Res. 26(12):3407–3416.
  • Hata K, Hori K, Ogasawara H, Takahashi S. 2003. Anti-leukemia activities of Lup-28-al-20(29)-en-3-one, a lupane triterpene. Toxicol Lett. 1:1–7.
  • Hata K, Ogawa S, Makino M, Mukaiyama T, Hori K, Iida T, Fujimoto Y. 2008. Lupane triterpenes with a carbonyl group at C-20 induce cancer cell apoptosis. J Nat Med. 62(3):332–335.
  • Jansen DJ, Shenvi RA. 2014. Synthesis of medicinally relevant terpenes: reducing the cost and time of drug discovery. Future Med Chem. 6(10):1127–1148.
  • Khan MF, Maurya CK, Dev K, Arha D, Rai AK, Tamrakar AK, Maurya R. 2014. Design and synthesis of lupeol analogues and their glucose uptake stimulatory effect in L6 skeletal muscle cells. Bioorg Med Chem Lett. 24(12):2674–2679.
  • Koeffler HP, Golde DW. 1980. Human myeloid leukemia cell lines: a review. Blood. 56(3):344–350.
  • Liu J, Zhang X, Zhong JF, Zhang C. 2017. CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia. Immunotherapy. 9(13):1115–1125.
  • Lozzio CB, Lozzio BB. 1975. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 45(3):321–334.
  • Machado VR, Sandjo LP, Moraes M, Pinheiro LG, Steindel M, Pizzolatti MG, Biavatti MW. 2018. Synthesis of lupeol derivatives and their antileishmanial and antitrypanosomal activities. Nat Prod Res. 32(3):275–281.
  • Maioral MF, Bodack CN, Stefanes NM, Bigolin A, Mascarello A, Chiaradia-Delatorre LD, Yunes RA, Nunes RJ, Santos-Silva MC. 2017. Cytotoxic effect of a novel naphthylchalcone against multiple cancer cells focusing on hematologic malignancies. Biochimie. 140:48–57.
  • Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 65(1–2):55–63.
  • Newman DJ, Cragg GM. 2016. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 79(3):629–661.
  • Nyaboke HO. 2018. Cytotoxicity of lupeol from the stem bark of Zanthoxylum gilletii against multi-factorial drug resistant cancer cell lines. Invest Med Chem Pharmacol. 10:1–6.
  • Ohmine K, Ota J, Ueda M, Ueno S, Yoshida K, Yamashita Y, Kirito K, Imagawa S, Nakamura Y, Saito K, et al. 2001. Characterization of stage progression in chronic myeloid leukemia by DNA microarray with furified hematopoietic stem cells. Oncogene. 20(57):8249–8257.
  • Schneider U, Schwenk HU, Bornkamm G. 1977. Characterization of EBV‐genome negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non‐Hodgkin lymphoma. Int J Cancer. 19(5):621–626.
  • Siddique HR, Saleem M. 2011. Beneficial health effects of lupeol triterpene: a review of preclinical studies. Life Sci. 88(7–8):285–293.
  • Surendra K, Corey E. 2009. A short enantioselective total synthesis of the fundamental pentacyclic triterpene lupeol. J Am Chem Soc. 131(39):13928–13929.
  • Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, et al. 2016. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 127(20):2375–2390E.
  • Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri AS, Stein H, Thiele J, Vardiman JW. 2017. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Geneva: WHO Press, 585 p.
  • Sykes DB, Haynes MK, Waller A, Garcia M, Ursu O, Gouveia KE, Sklar L, Lewis TA, Dandapani S, Munoz B, et al. 2010. In probe reports from the NIH molecular libraries program. Bethesda (MD): National Center for Biotechnology Information (US). https://www.ncbi.nlm.nih.gov/books/NBK280053/.
  • Wang JJ, Liu KS, Sung KC, Tsai CY, Fang J. 2009. Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection. Eur J Pharm Sci. 38(2):138–146.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.